RP1 virus therapy for advanced melanoma to lower lymph node spread risk
Part of Cancer, Skin clinical trials.
This trial tests a new kind of virus-based treatment (RP1) given directly into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. It's for people with thicker or more advanced skin melanoma that still has visible tumor or positive margins after biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and willing to sign a consent form.
- Your melanoma must be a specific deep or advanced stage (pT3b, T4a, or T4b) and still have visible tumor or a positive margin on biopsy.
- You must be generally healthy and active (able to do light work or be up and about).
- You cannot have had prior treatment with an oncolytic virus or have active serious infections like hepatitis B, C, or HIV.
- You must not be on high-dose steroids or have other conditions that would interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new virus-based treatment for advanced melanoma that has spread to the brain or other parts of the body. The virus is injected directly into a tumor to try to kill it, and it may boost your immune system against the cancer.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
This study checks the long-term safety of patients who have already received RP1, RP2, or RP3 treatment in a previous study. It helps doctors understand any side effects that may appear over time.
This trial tests two drugs given before surgery to shrink melanoma that has spread to lymph nodes. The goal is to see if this combination helps remove the cancer more effectively.
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.